PT  - JOURNAL ARTICLE
AU  - Patel, Faeezah
AU  - Le Roux, Jean
AU  - Sawry, Shobna
AU  - Kieser, Robert
AU  - Dhar, Mrinmayee
AU  - Gill, Katherine
AU  - Lazarus, Erica
AU  - Nana, Anusha
AU  - Garrett, Nigel
AU  - Moore, Penny L
AU  - Sigal, Alex
AU  - Gray, Glenda
AU  - Rees, Helen V
AU  - Jacobson, Barry Frank
AU  - Fairlie, Lee
TI  - Clot Twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS
AID  - 10.1101/2024.02.19.24303026
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.19.24303026
4099  - http://medrxiv.org/content/early/2024/02/21/2024.02.19.24303026.short
4100  - http://medrxiv.org/content/early/2024/02/21/2024.02.19.24303026.full
AB  - BaSiS (Booster After Sisonke Study) is a prospectively enrolled open-label trial in which healthy adults, with controlled co-morbidities and no prior thrombosis, who received a single Ad26.COV2.S prime vaccination primarily through the Sisonke phase IIIB open label implementation study in South Africa. An exploratory objective evaluated the clotting profiles of participants who were enrolled across 4 sites in South Africa and randomised 1:1:1:1 to receive one of full-dose Ad26.COV2.S, half-dose Ad26.COV2.S, full-dose Comirnaty or half-dose Comirnaty booster. D-dimer testing (INNOVANCE®D-Dimer Assay), as a coagulopathy marker, was conducted pre-booster (baseline) and 2 weeks post-booster. The median age among 285 participants was 42.2 years (IQR:35.5-48.7), 235/285 (82.5%) were female, 269/285 (94.4%) were Black African. Of the 40.4% (115/285) people living with HIV (PLHIV), 79.1% (91/115) were well-controlled on antiretroviral therapy. At baseline, 39.3% (112/285) had elevated d-dimers; all asymptomatic. Females and obese participants were significantly more likely to have elevated baseline d-dimers (OR=4.17; 95% CI:1.88 to 9.26 and OR=2.64; 95% CI:1.57 to 4.43, respectively). Of 169 with normal baseline d-dimers, 29 (17.2%) became elevated 2 weeks post-booster: median increase 0.23µg/ml (IQR:0.15-0.42); those receiving full-dose Comirnaty exhibited lower risk of d-dimer elevation post vaccination, compared to other booster vaccination arms (OR:0.26; 95% CI:0.07 to 0.98). PLHIV experienced significantly higher median increases compared to HIV uninfected participants (0.43 vs 0.17, p=0.004). Elevated d-dimers in asymptomatic, low-risk adults were unexpectedly common but were not associated with thromboembolism, supporting the rationale of using d-dimers only if clinically indicated. Trial Registration: South African Clinical Trails Register number DOH-27-012022-7841.Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: FP, MD: Support for the present manuscript - Bill and Melinda Gates Foundation, through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program (INV-030570) and the Wellcome Trust (226137/Z/22/Z); SAMRC. Both paid to institution. Grants/ contracts - Received grant funding from Janssen to conduct the following clinical trials: Ensemble study (3UM1 AI068614-14SI), Sherpa Study (96867), Sisonke 1 study (96833), Horizon 1 (VAC31518COV2004), Horizon 2 (VAC31518COV3006). Received grant funding from Pfizer to conduct the following clinical trials:C4591015. All paid to institution. SS, JLR: Support for the present manuscript - SAMRC (paid to institution), South African National Department of Health (SA NDoH) - Sponsor of Comirnaty, Janssen Pharmaceuticals - Sponsor of Janssen Ad26.COV2.S. Grants/ contracts - CDC, BMGF, Wellcome Trust, EU, EDCTP. All paid to institution. LF: Support for the present manuscript - Bill and Melinda Gates Foundation, through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program (INV-030570) and the Wellcome Trust (226137/Z/22/Z); SAMRC. Both paid to institution. Participation on a Data Safety Monitoring Board or Advisory Board: MIGHTY-MO Study (DSMB Chair), Petite-DTG study (DSMB Member). Leadership or fiduciary role: IMPAACT Therapeutic Scientific Committee PLM: Support for the present manuscript - Bill and Melinda Gates Foundation; SAMRC. Both paid to institution. AS: Support for the present manuscript - Bill and Melinda Gates Foundation. Sub-award to institution. BFJ: Consulting fees - Sanofi, Aspen, AstraZeneca, Zyquis. Payment for expert testimony - Medicolegal cases of thrombosis problems Support for attending meetings and/or travel: Aspen - To attend ESC and teach on returnClinical TrialDOH-27-012022-7841Funding StatementThis study was funded by: SAMRC (South African Medical Research Council) - https://www.samrc.ac.za/ Sponsor of Comirnaty: South African National Department of Health SA NDoH - https://www.health.gov.za/ Sponsor of Janssen Ad26.COV2.S: Janssen Pharmaceuticals - https://www.janssen.com/ SAMRC played a role in study design, decision to publish, and preparation of the manuscript. SA NDoH and Janssen Pharmaceuticals did not play any additional roles beyond vaccine sponsorship. FP, MD: Support for the present manuscript - SAMRC. Paid to institution. SS, JLR: Support for the present manuscript - SAMRC (paid to institution), South African National Department of Health (SA NDoH) - Sponsor of Comirnaty, Janssen Pharmaceuticals - Sponsor of Janssen Ad26.COV2.S. LF: Grants/ contracts - SAMRC. PLM: Support for the present manuscript - Bill and Melinda Gates Foundation; SAMRC. Both paid to institution. AS: Support for the present manuscript - Bill and Melinda Gates Foundation. Sub-award to institution.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BaSiS study was approved by Wits University's Human Research Ethics Committee (Reference no 211001B), Biomedical Research Ethics Committee (Reference no BREC/00003487/2021), University of Cape Town (UCT) Faculty of Health Sciences Human Research Ethics Committee (Reference no 680/2021) and the South African Health Products Regulatory Authority (SAHPRA Reference no 20210423).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes